Rethinking PID - Why the distinction between primary and secondary immune disorders is relevant more frequently than between inborn and acquired errors of immunity

Markus G. Seidel

DOI: https://doi.org/10.1016/j.jaci.2024.01.018

IF: 14.29

2024-02-05

Journal of Allergy and Clinical Immunology

Abstract:Graphical abstract Download : Download high-res image (293KB) Download : Download full-size image

immunology,allergy

What problem does this paper attempt to address?

Immune deficiency and the gut

Lucy Leeman

DOI: https://doi.org/10.1016/j.mpmed.2024.01.009

IF: 1.6

2024-02-01

Medicine

Abstract:Primary immunodeficiency disorders (PID), also referred to as inborn errors of immunity, are rare but are commonly associated with gastrointestinal (GI) disease. Gastroenterologists provide an important contribution to the long-term management of these complex patients. This article aims to raise awareness of PID-associated GI complications and highlight key features within GI presentations that may indicate an underlying PID.

medicine, general & internal
Too much of a good thing: a review of primary immune regulatory disorders

Christo Tsilifis,Mary A Slatter,Andrew R Gennery

DOI: https://doi.org/10.3389/fimmu.2023.1279201

2023-10-31

Abstract:Primary immune regulatory disorders (PIRDs) are inborn errors of immunity caused by a loss in the regulatory mechanism of the inflammatory or immune response, leading to impaired immunological tolerance or an exuberant inflammatory response to various stimuli due to loss or gain of function mutations. Whilst PIRDs may feature susceptibility to recurrent, severe, or opportunistic infection in their phenotype, this group of syndromes has broadened the spectrum of disease caused by defects in immunity-related genes to include autoimmunity, autoinflammation, lymphoproliferation, malignancy, and allergy; increasing focus on PIRDs has thus redefined the classical 'primary immunodeficiency' as one aspect of an overarching group of inborn errors of immunity. The growing number of genetic defects associated with PIRDs has expanded our understanding of immune tolerance mechanisms and prompted identification of molecular targets for therapy. However, PIRDs remain difficult to recognize due to incomplete penetrance of their diverse phenotype, which may cross organ systems and present to multiple clinical specialists prior to review by an immunologist. Control of immune dysregulation with immunosuppressive therapies must be balanced against the enhanced infective risk posed by the underlying defect and accumulated end-organ damage, posing a challenge to clinicians. Whilst allogeneic hematopoietic stem cell transplantation may correct the underlying immune defect, identification of appropriate patients and timing of transplant is difficult. The relatively recent description of many PIRDs and rarity of individual genetic entities that comprise this group means data on natural history, clinical progression, and treatment are limited, and so international collaboration will be needed to better delineate phenotypes and the impact of existing and potential therapies. This review explores pathophysiology, clinical features, current therapeutic strategies for PIRDs including cellular platforms, and future directions for research.
Autoimmunity as a continuum in primary immunodeficiency

Jolan E Walter,Irmel A Ayala,Diana Milojevic

DOI: https://doi.org/10.1097/MOP.0000000000000833

Abstract:Purpose of review: Primary immunodeficiency disorders (PIDs) are no longer defined by infections alone. First clinical sign or sequelae of PID may include autoimmunity, such as cytopenias, arthritis or enteropathy. This review addresses the latest in multidisciplinary approaches for expanding clinical phenotypes of PIDs with autoimmunity, including new presentations of known entities and novel gene defects. We also discuss diagnostic tools for identifying the distinct changes in immune cells subsets and autoantibodies, mechanistic understanding of the process, and targeted treatment and indications for hematopoietic stem-cell transplantation (HSCT). Recent findings: In the past years, increased awareness and use of genetic screening, confirmatory functional studies and immunological biomarkers opened the door for early recognition of PIDs among patients with autoimmunity. Large cohort studies detail the clinical spectrum and treatment outcome of PIDs with autoimmunity with specific immune genes (e.g., CTLA4, LRBA, PI3Kδ, NFKB1, RAG). The benefit of early recognition is initiation of targeted therapies with precise re-balancing of the dysregulated immune pathways (e.g., biologicals) or definitive therapy (e.g., HSCT). Summary: Clinical presentation of patients with PID and autoimmunity is highly variable and requires in-depth diagnostics and precision medicine approaches.
Immunodeficiency: Overview of primary immune regulatory disorders (PIRDs)

Cody S Nelson,Carolyn H Baloh

DOI: https://doi.org/10.2500/aap.2024.45.240070

2024-09-01

Abstract:Primary immune regulatory disorders (PIRD) comprise a heterogeneous group of monogenic disorders that impact homeostatic control of inflammation and immune tolerance. Patients with a PIRD typically present to medical care with symptoms of autoimmunity or hyperinflammation as the dominant clinical feature, symptoms that include fever, rash, lymphadenopathy, organomegaly, arthritis, and colitis are commonplace. Notably, PIRDs are a distinct entity from primary immune deficiency disorders (PIDD), which are primarily defined by a qualitative or quantitative defect in immunity, which manifests as a susceptibility to recurrent infections. PIDDs and PIRDs can be challenging to differentiate because the clinical presentations can be similar. Red flags for PIRDs include multiple autoimmune diagnoses in the same patient, chronic lymphadenopathy, hepatomegaly, and/or splenomegaly, chronic colitis, hemophagocytic lymphohistiocytosis (HLH), Epstein Barr virus (EBV) susceptibility, recurrent or persistent fever, vasculitis, and sterile inflammation. For simplicity in this brief review, we limit our discussion of PIRDs to the following categories multiple autoimmune diseases, immune dysregulation with colitis, disorders with HLH and/or EBV susceptibility, autoinflammatory syndromes, type 1 interferonopathies, and disorders of sterile inflammation. Diagnosing a PIRD requires a broad immune evaluation for both immune system deficiencies and inflammation, along with genetic testing. Given the complex nature of these diseases, treatment often requires a team of subspecialists. Treatment, depending on the specific diagnosis, may be somewhat empiric with nonspecific immune modulators, symptom-directed therapies, and, in severe cases, hematopoietic stem cell transplantation; however, with the increasing number of biologics available, we are often able to use targeted immune therapy or even gene therapy.
Infections in Disorders of Immune Regulation

Abarna Thangaraj,Reva Tyagi,Deepti Suri,Sudhir Gupta

DOI: https://doi.org/10.3390/pathogens13030259

IF: 3.7

2024-03-17

Pathogens

Abstract:Primary immune regulatory disorders (PIRDs) constitute a spectrum of inborn errors of immunity (IEIs) that are primarily characterized by autoimmunity, lymphoproliferation, atopy, and malignancy. In PIRDs, infections are infrequent compared to other IEIs. While susceptibility to infection primarily stems from antibody deficiency, it is sometimes associated with additional innate immune and T or NK cell defects. The use of immunotherapy and chemotherapy further complicates the immune landscape, increasing the risk of diverse infections. Recurrent sinopulmonary infections, particularly bacterial infections such as those associated with staphylococcal and streptococcal organisms, are the most reported infectious manifestations. Predisposition to viral infections, especially Epstein–Barr virus (EBV)-inducing lymphoproliferation and malignancy, is also seen. Notably, mycobacterial and invasive fungal infections are rarely documented in these disorders. Knowledge about the spectrum of infections in these disorders would prevent diagnostic delays and prevent organ damage. This review delves into the infection profile specific to autoimmune lymphoproliferative syndrome (ALPS), Tregopathies, and syndromes with autoimmunity within the broader context of PIRD. Despite the critical importance of understanding the infectious aspects of these disorders, there remains a scarcity of comprehensive reports on this subject.

microbiology
Dissecting Secondary Immunodeficiency: Identification of Primary Immunodeficiency within B-Cell Lymphoproliferative Disorders

María Palacios-Ortega,Teresa Guerra-Galán,Adolfo Jiménez-Huete,José María García-Aznar,Marc Pérez-Guzmán,Maria Dolores Mansilla-Ruiz,Ángela Villegas Mendiola,Cristina Pérez López,Elsa Mayol Hornero,Alejandro Peixoto Rodriguez,Ascensión Peña Cortijo,Marta Polo Zarzuela,Marta Mateo Morales,Eduardo Anguita Mandly,Maria Cruz Cárdenas,Alejandra Carrero,Carlos Jiménez García,Estefanía Bolaños,Belén Íñigo,Fiorella Medina,Eduardo de la Fuente,Juliana Ochoa-Grullón,Blanca García-Solís,Yolanda García-Carmona,Miguel Fernández-Arquero,Celina Benavente-Cuesta,Rebeca Pérez de Diego,Nicholas Rider,Silvia Sánchez-Ramón

DOI: https://doi.org/10.1007/s10875-024-01818-2

2024-10-23

Abstract:Distinguishing between primary (PID) and secondary (SID) immunodeficiencies, particularly in relation to hematological B-cell lymphoproliferative disorders (B-CLPD), poses a major clinical challenge. We aimed to analyze and define the clinical and laboratory variables in SID patients associated with B-CLPD, identifying overlaps with late-onset PIDs, which could potentially improve diagnostic precision and prognostic assessment. We studied 37 clinical/laboratory variables in 151 SID patients with B-CLPD. Patients were classified as "Suspected PID Group" when having recurrent-severe infections prior to the B-CLPD and/or hypogammaglobulinemia according to key ESID criteria for PID. Bivariate association analyses showed significant statistical differences between "Suspected PID"- and "SID"-groups in 10 out of 37 variables analyzed, with "Suspected PID" showing higher frequencies of childhood recurrent-severe infections, family history of B-CLPD, significantly lower serum Free Light Chain (sFLC), immunoglobulin concentrations, lower total leukocyte, and switch-memory B-cell counts at baseline. Rpart machine learning algorithm was performed to potentially create a model to differentiate both groups. The model developed a decision tree with two major variables in order of relevance: sum κ + λ and history of severe-recurrent infections in childhood, with high sensitivity 89.5%, specificity 100%, and accuracy 91.8% for PID prediction. Identifying significant clinical and immunological variables can aid in the difficult task of recognizing late-onset PIDs among SID patients, emphasizing the value of a comprehensive immunological evaluation. The differences between "Suspected PID" and SID groups, highlight the need of early, tailored diagnostic and treatment strategies for personalized patient management and follow up.
Invasive Fungal Infection in Primary Immunodeficiencies Other Than Chronic Granulomatous Disease

A. Garraffo,B. Pilmis,J. Toubiana,A. Puel,N. Mahlaoui,S. Blanche,O. Lortholary,F. Lanternier

DOI: https://doi.org/10.1007/s12281-017-0273-x

2017-03-01

Current Fungal Infection Reports

Abstract:Purpose of reviewWe aimed to review invasive fungal infections complicating primary immunodeficiencies (PID).Recent findingsSeveral PID predisposing to fungal infections were recently deciphered. CARD9 deficiency selectively predisposes to fungal infections including candidiasis, aspergillosis, deep dermatophytosis, and phaeohyphomycosis, with frequent central nervous system location, especially after Candida infection. Patients with heterozygous STAT1 gain-of-function mutations are mostly predisposed to chronic mucocutaneous candidiasis but may also display, even though less frequently, invasive fungal infections. Aspergillosis complicating STAT3 deficiency is also a major concern in patients with lung cavities. Antifungal prophylaxis is recommended in this first group of patients. Previously well-reported PID are known to predispose to fungal infections, such as genetic defects impairing the IL-12/IFN-γ axis can predispose to cryptococcosis, and dimorphic fungal infections.SummaryPatients developing invasive fungal infections including candidiasis, aspergillosis, cryptococcosis, phaeohyphomycosis, pneumocystosis, or disseminated infections caused by dimorphic fungi, without known underlying risk factors, should be explored immunogenetically in order to diagnose primary immunodeficiencies, even in the absence of previous other infectious episodes.
The altered landscape of the human skin microbiome in patients with primary immunodeficiencies

Julia Oh,Alexandra F. Freeman,Morgan Park,Robert Sokolic,Fabio Candotti,Steven M. Holland,Julia A. Segre,Heidi H. Kong,,

DOI: https://doi.org/10.1101/gr.159467.113

IF: 9.438

2013-10-29

Genome Research

Abstract:While landmark studies have shown that microbiota activate and educate host immunity, how immune systems shape microbiomes and contribute to disease is incompletely characterized. Primary immunodeficiency (PID) patients suffer recurrent microbial infections, providing a unique opportunity to address this issue. To investigate the potential influence of host immunity on the skin microbiome, we examined skin microbiomes in patients with rare monogenic PIDs: hyper-IgE (STAT3-deficient), Wiskott-Aldrich, and dedicator of cytokinesis 8 syndromes. While specific immunologic defects differ, a shared hallmark is atopic dermatitis (AD)–like eczema. We compared bacterial and fungal skin microbiomes (41 PID, 13 AD, 49 healthy controls) at four clinically relevant sites representing the major skin microenvironments. PID skin displayed increased ecological permissiveness with altered population structures, decreased site specificity and temporal stability, and colonization with microbial species not observed in controls, including Clostridium species and Serratia marcescens . Elevated fungal diversity and increased representation of opportunistic fungi ( Candida, Aspergillus ) supported increased PID skin permissiveness, suggesting that skin may serve as a reservoir for the recurrent fungal infections observed in these patients. The overarching theme of increased ecological permissiveness in PID skin was counterbalanced by the maintenance of a phylum barrier in which colonization remained restricted to typical human-associated phyla. Clinical parameters, including markers of disease severity, were positively correlated with prevalence of Staphylococcus , Corynebacterium , and other less abundant taxa. This study examines differences in microbial colonization and community stability in PID skin and informs our understanding of host–microbiome interactions, suggesting a bidirectional dialogue between skin commensals and the host organism.

genetics & heredity,biochemistry & molecular biology,biotechnology & applied microbiology
Multilayer concept of autoimmune mechanisms and manifestations in inborn errors of immunity : Relevance for precision therapy

Markus G. Seidel,Fabian Hauck

DOI: https://doi.org/10.1016/j.jaci.2023.12.022

IF: 14.29

2024-01-07

Journal of Allergy and Clinical Immunology

Abstract:Autoimmunity in inborn errors of immunity (IEI) has a multifactorial pathogenesis and develops upon a genetic predisposition in conjunction with gene regulation, environmental modifiers, and infectious triggers. Based on incremental data availability due to up-front application of omics-technologies, a more granular and dynamic view of mechanisms and manifestations is warranted. Here we present a comprehensive novel concept of autoimmunity in IEI that considers multiple layers of interdependent elements and connects 101 causative genes or deletions according to the quality of the allelic variants with 47 molecular pathways and 22 immune effector mechanisms. Furthermore, we list 50 resulting manifestations together with the corresponding human phenotype ontology (HPO) terms and review the types and frequencies of the most relevant clinical presentations. Together, this concept, i) , extends the historical anatomical view of central versus peripheral tolerance towards multiple interdependent mechanisms of immune tolerance, ii) , delineates the mechanisms underlying the protean clinical manifestations, and thereby, iii) , points towards the most suitable precision therapy for autoimmunity in IEI. The multilayer concept of autoimmune mechanisms and manifestations in IEI will facilitate research design and provide clinical guidance on the use of precision medicine irrespective of the data depth available in each health care scenario.

immunology,allergy
Human primary immunodeficiency diseases: a perspective

Alain Fischer

DOI: https://doi.org/10.1038/ni1023

IF: 30.5

2003-12-29

Nature Immunology

Abstract:Primary immunodeficiency diseases consist of a group of more than 100 inherited conditions, mostly monogenic, predisposing individuals to different sets of infections, allergy, autoimmunity and cancer. Primary immunodeficiencies therefore represent exquisite models of various immunopathological settings. The identification of the associated genes, 100 so far, has generated a plethora of information about the immune system and spurred the analysis of many aspects of the development, function and regulation of both innate and adaptive immunity. These findings can potentially contribute to improved care of affected individuals by providing new diagnostic and/or therapeutic tools.

immunology
Overview of secondary immunodeficiency

Katherine E Herman,Katherine L Tuttle

DOI: https://doi.org/10.2500/aap.2024.45.240063

2024-09-01

Abstract:In contrast to inborn errors of immunity (IEI), which are inherited disorders of the immune system that predispose to infections, malignancy, atopy, and immune dysregulation, secondary immunodeficiencies and immune dysregulation states (SID) are acquired impairments in immune cell function and/or regulation, and may be transient, reversible, or permanent. SIDs can derive from a variety of medical comorbidities, including protein-losing conditions, malnutrition, malignancy, certain genetic syndromes, prematurity, and chronic infections. Medications, including immunosuppressive and chemotherapeutic drugs, can have profound effects on immunity and biologic agents used in rheumatology, neurology, and hematology/oncology practice are increasingly common causes of SID. Iatrogenic factors, including surgical procedures (thymectomy, splenectomy) can also contribute to SID. A thorough case history, medication review, and laboratory evaluation are necessary to identify the primary driver and determine proper management of SID. Careful consideration should be given to whether a primary IEI could be contributing to autoimmunity, malignancy, and posttreatment complications (e.g., antibody deficiency). SID management consists of addressing the driving condition and/or removing the offending agent if feasible. If SID is suspected to be permanent, then antibiotic prophylaxis, additional immunization, and immunoglobulin replacement should be considered.
Epigenetic immune cell quantification for diagnostic evaluation and monitoring of patients with inborn errors of immunity and secondary immune deficiencies

Neftali J Ramirez,Janika J Schulze,Steffi Walter,Jeannette Werner,Pavla Mrovecova,Sven Olek,Christoph Sachsenmaier,Bodo Grimbacher,Ulrich Salzer

DOI: https://doi.org/10.1016/j.clim.2024.109920

Abstract:Background: Early detection and monitoring of primary immunodeficiencies (PID) in humans require quantitative determination of immune cells from fresh blood analyzed by flow cytometry. However, epigenetic immune cell quantification allows analysis from fresh, frozen, or dried blood samples. We demonstrate the utility of epigenetic immune cell quantification for patients with PID. Methods: Epigenetic quantification of basic lymphocyte subpopulations of 259 samples from PID patients were compared to flow cytometric data. Epigenetic analysis was extended to T-cell subsets (Treg, Th17, Tfh, PD-1+, CCR6+) and memory B-cells and compared between venous EDTA and dried blood. Results: A high correlation of >0.9 was observed for basic T- and B-cell subsets. Extended epigenetic analysis showed quantitative trends within PID subgroups, but individually these varied substantially within these groups. Epigenetic analysis of dried blood samples was equivalent to EDTA blood. Conclusion: Epigenetic immune cell quantification is suitable for immune cell profiling in PID patients.
Primary Immunodeficiency As a Cause of Immune-Mediated Kidney Diseases

Changming Zhang,Dandan Liang,Zhihong Liu

DOI: https://doi.org/10.1093/ndt/gfae117

2024-01-01

Abstract:Primary immunodeficiency (PID) is no longer defined by infections alone, and autoimmunity is an accompanying manifestation of PID. Recurrent infections may trigger autoimmunity through molecular mimicry, bystander activation or superantigens. The diagnosis of PID is still challenging, but genetic analysis reveals the underlying link between PID and autoimmunity. Mutations in relevant genes affecting central and peripheral immune tolerance, regulatory T-cell function, expansion of autoreactive lymphocytes, antigen clearance, hyperactivation of type I interferon and nuclear factor-kappa B pathways have all been implicated in triggering autoimmunity in PID. Autoimmunity in PID leads to chronic inflammation, tissue damage and organ failure, and increases the mortality of patients with PID. The kidneys are inextricably linked with the immune system, and kidney diseases can be mediated by both infection and autoimmunity/inflammation in PID patients. The manifestations of kidney involvement in PID patients are very heterogeneous and include lupus nephritis, C3 glomerulopathy, kidney thrombotic microangiopathy, vasculitis and interstitial nephritis. Patients with PID-caused kidney diseases have defined immune function defects and may benefit from pathway-based biologics, stem cell transplantation or gene therapy. Early diagnosis and appropriate treatment of PID are crucial for reducing the mortality rate and improving organ function and quality of life.
Physician awareness and understanding of primary immunodeficiency disorders: a web-based study in Japan

Kohsuke Imai,Akinori Oh,Ayumi Morishita,Yoichi Inoue

DOI: https://doi.org/10.1080/25785826.2022.2137966

2022-11-05

Immunological Medicine

Abstract:Primary immunodeficiencies (PIDs)/Inborn errors of immunity (IEI) consist of a complex genetic group of disorders that cause susceptibility to infections, inflammation, immune dysregulation, autoimmunity, and malignancy. One of the key steps to reach an early diagnosis is improving knowledge of PID among the medical community. In this study, a web-based survey was conducted among 355 Japanese physicians, consisting of 121 pediatricians, 116 hematologists, and 118 general internal medicine physicians, to assess their awareness and knowledge about the diagnostic flow of PID. One of the major problems this study identified was the unawareness of optimal IgG trough levels among the physicians, while around half the physicians knew about the symptoms of PID. Results from the hypothetical case study revealed that over 70% of physicians considered PID after obtaining the past medical history of patients and 75.2% of physicians showed interest in gaining more knowledge about PID. The survey findings revealed that proper questioning to understand the exact medical history of patients may lead to basic immunological examination. There is a need to improve knowledge about PID, e.g., the '10 warning signs of PID' and '4 stages of testing for PID', and to motivate physicians to ensure earlier diagnosis of PID.
Inborn Errors of Immunity in Early Childhood: Essential Insights for the Neonatologist

Johannes Dirks,Matthias Wölfl,Christian P Speer,Christoph Härtel,Henner Morbach

DOI: https://doi.org/10.1159/000540436

Neonatology

Abstract:Background: Inborn errors of immunity (IEI), formerly referred to as primary immunodeficiencies, manifest with a wide range of symptoms such as increased susceptibility to infections, immune dysregulation, and autoinflammation. Although most cases manifest in childhood, onset during the neonatal period is rare but potentially critical. Summary: In this review, we discuss the diverse clinical presentations of IEI and the specific challenges they pose to neonatologists. Rather than detailing every molecular defect, we focus on common clinical scenarios in neonates and young infants, providing practical diagnostic strategies to ensure timely and effective therapeutic interventions. Key messages: Clinical presentations of IEI in neonates may include delayed separation of the umbilical cord, skin rashes such as eczema and erythroderma, and recurrent episodes of inflammation. We also highlight immunological emergencies that require urgent medical attention, such as hyperinflammatory activity mimicking acute neonatal liver failure, sometimes seen in hemophagocytic lymphohistiocytosis. We also discuss appropriate medical action in the case of a positive newborn screening for severe T-cell defects. Early medical intervention in such circumstances may significantly improve outcomes.
Functional genomics in inborn errors of immunity

Charlotte Hurabielle,Taylor N. LaFlam,Melissa Gearing,Chun Jimmie Ye

DOI: https://doi.org/10.1111/imr.13309

2024-02-10

Immunological Reviews

Abstract:Summary Inborn errors of immunity (IEI) comprise a diverse spectrum of 485 disorders as recognized by the International Union of Immunological Societies Committee on Inborn Error of Immunity in 2022. While IEI are monogenic by definition, they illuminate various pathways involved in the pathogenesis of polygenic immune dysregulation as in autoimmune or autoinflammatory syndromes, or in more common infectious diseases that may not have a significant genetic basis. Rapid improvement in genomic technologies has been the main driver of the accelerated rate of discovery of IEI and has led to the development of innovative treatment strategies. In this review, we will explore various facets of IEI, delving into the distinctions between PIDD and PIRD. We will examine how Mendelian inheritance patterns contribute to these disorders and discuss advancements in functional genomics that aid in characterizing new IEI. Additionally, we will explore how emerging genomic tools help to characterize new IEI as well as how they are paving the way for innovative treatment approaches for managing and potentially curing these complex immune conditions.

immunology
Immunodysregulation in immunodeficiency

Christopher Chang

DOI: https://doi.org/10.2500/aap.2024.45.240058

2024-09-01

Abstract:The primary immunodeficiency diseases are often accompanied by autoimmunity, autoinflammatory, or aberrant lymphoproliferation. The paradoxical nature of this association can be explained by the multiple cells and molecules involved in immune networks that interact with each other in synergistic, redundant, antagonistic, and parallel arrangements. Because progressively more immunodeficiencies are found to have a genetic etiology, in many cases, a monogenic pathology, an understanding of why immunodeficiency is really an immune dysfunction becomes evident. Understanding the role of specific genes allows us to better understand the complete nature of the inborn error of immunity (IEI); the latter is a term generally used when a clear genetic etiology can be discerned. Autoimmune cytopenias, inflammatory bowel disease, autoimmune thyroiditis, and autoimmune liver diseases as well as lymphomas and cancers frequently accompany primary immunodeficiencies, and it is important that the practitioner be aware of this association and to expect that this is more common than not. The treatment of autoimmune or immunodysregulation in primary immunodeficiencies often involves further immunosuppression, which places the patient at even greater risk of infection. Mitigating measures to prevent such an infection should be considered as part of the treatment regimen. Treatment of immunodysregulation should be mechanism based, as much as we understand the pathways that lead to the dysfunction. Focusing on abnormalities in specific cells or molecules, e.g., cytokines, will become increasingly used to provide a targeted approach to therapy, a prelude to the success of personalized medicine in the treatment of IEIs.
Bridging the gap: neurodevelopmental disorder risks in inborn errors of immunity

Devika Kurup,Amy M. FitzPatrick,Aleksandra Badura,Ines Serra

DOI: https://doi.org/10.1097/aci.0000000000001036

2024-10-05

Current Opinion in Allergy and Clinical Immunology

Abstract:Inborn errors of immunity (IEI) are characterized by increased susceptibility to infections, autoimmunity, atopy, and malignancies. Although each disease is individually rare, IEIs as a group affect between 1 : 1000 and 1 : 5000 people [1▪] . IEI research has predominantly focused on the immunological and oncological manifestations, genetic causes, and treatment options, which range from immunoglobulin replacement to hematopoietic stem cell transplant [2,3,8] . In recent years, however, there has been growing interest in multiorgan presentations, with reports describing comorbidities of the central nervous, gastrointestinal, and hepatic systems [1▪,2] .

immunology,allergy
Vaccination status of patients with primary immunodeficiencies in Germany-a multicentric epidemiologic analysis

Eva C Schwaneck,Anna S Harasim,Hans-Peter Tony,Micha Gawlik,Torsten Witte,Stefanie Joos,Michael Gernert,Marc Schmalzing,Henner Morbach,Matthias Fröhlich,Manuel Krone

DOI: https://doi.org/10.1007/s00393-024-01549-0

2024-08-22

Abstract:Background: Vaccinations represent an easily accessible, safe, and important method for preventing infections. Patients with primary immunodeficiencies (PID) are more susceptible to infections and should receive an extended spectrum of immunizations in many countries. Methods: Between January 2019 and May 2020, vaccination certificates of 70 patients with PID from the regions of Würzburg and Hanover in Germany were evaluated. The patients were additionally surveyed regarding their attitude towards vaccinations and the communication with their physicians. Medical records were analyzed. Results: Of the 70 patients, 54 (77%) suffered from common variable immunodeficiency, 30 (43%) were diagnosed with accompanying autoimmunity, 62 (89%) had an increased susceptibility to infections, and 56 (80%) were on immunoglobulin substitution therapy. Seven patients (10%) had neither a vaccination certificate nor were they able to recollect of their last vaccination. Only 55 (79%) and 43 (61%) patients stated that their rheumatologist or immunologist had recommended an influenza and a pneumococcal vaccination, respectively. When asked about their overall trust in vaccinations on a scale of 0 to 10 (0 = very low, 10 = very high), the mean value was 7.8. The most common vaccination was against tetanus in 63 (90%) patients, 49 (70%) had received vaccination against pneumococci, and 39 (56%) had received an influenza vaccination. Interestingly, 26 patients (37%) were vaccinated against measles, even though this is contraindicated in most PID patients. Conclusion: Our data suggest that vaccination rates in this at-risk population are insufficient. Healthcare providers should emphasize vaccinations routinely when caring for these patients.
Diagnostic yield of next-generation sequencing in suspect primary immunodeficiencies diseases: a systematic review and meta-analysis

Yingying Chen,Dongrui Li,Jiawen Yin,Jinglin Xiong,Min Xu,Qing Qi,Wenlin Yang

DOI: https://doi.org/10.1007/s10238-024-01392-2

IF: 4.6

2024-06-20

Clinical and Experimental Medicine

Abstract:To determine the diagnostic yield of Next-generation sequencing (NGS) in suspect Primary Immunodeficiencies Diseases (PIDs). This systematic review was conducted following PRISMA criteria. Searching Pubmed and Web of Science databases, the following keywords were used in the search: ("Next-generation sequencing") OR "whole exome sequencing" OR "whole genome sequencing") AND ("primary immunodeficiency disease" OR "PIDs"). We used STARD items to assess the risk of bias in the included studies. The meta-analysis included 29 studies with 5847 patients, revealing a pooled positive detection rate of 42% (95% CI 0.29–0.54, P < 0.001) for NGS in suspected PID cases. Subgroup analyses based on family history demonstrated a higher detection rate of 58% (95% CI 0.43–0.71) in patients with a family history compared to 33% (95% CI 0.21–0.46) in those without ( P < 0.001). Stratification by disease types showed varied detection rates, with Severe Combined Immunodeficiency leading at 58% ( P < 0.001). Among 253 PID-related genes, RAG1, ATM, BTK, and others constituted major contributors, with 34 genes not included in the 2022 IUIS gene list. The application of NGS in suspected PID patients can provide significant diagnostic results, especially in patients with a family history. Meanwhile, NGS performs excellently in accurately diagnosing disease types, and early identification of disease types can benefit patients in treatment.

medicine, research & experimental

Rethinking PID - Why the distinction between primary and secondary immune disorders is relevant more frequently than between inborn and acquired errors of immunity

Immune deficiency and the gut

Too much of a good thing: a review of primary immune regulatory disorders

Autoimmunity as a continuum in primary immunodeficiency

Immunodeficiency: Overview of primary immune regulatory disorders (PIRDs)

Infections in Disorders of Immune Regulation

Dissecting Secondary Immunodeficiency: Identification of Primary Immunodeficiency within B-Cell Lymphoproliferative Disorders

Invasive Fungal Infection in Primary Immunodeficiencies Other Than Chronic Granulomatous Disease

The altered landscape of the human skin microbiome in patients with primary immunodeficiencies

Multilayer concept of autoimmune mechanisms and manifestations in inborn errors of immunity : Relevance for precision therapy

Human primary immunodeficiency diseases: a perspective

Overview of secondary immunodeficiency

Epigenetic immune cell quantification for diagnostic evaluation and monitoring of patients with inborn errors of immunity and secondary immune deficiencies

Primary Immunodeficiency As a Cause of Immune-Mediated Kidney Diseases

Physician awareness and understanding of primary immunodeficiency disorders: a web-based study in Japan

Inborn Errors of Immunity in Early Childhood: Essential Insights for the Neonatologist

Functional genomics in inborn errors of immunity

Immunodysregulation in immunodeficiency

Bridging the gap: neurodevelopmental disorder risks in inborn errors of immunity

Vaccination status of patients with primary immunodeficiencies in Germany-a multicentric epidemiologic analysis

Diagnostic yield of next-generation sequencing in suspect primary immunodeficiencies diseases: a systematic review and meta-analysis